More than five years after its publication, a 2020 laboratory study on honeybee venom and breast cancer continues to draw attention as researchers seek new options for aggressive, hard-to-treat forms of the disease.
A study found honeybee venom destroyed 2 types of hard to treat breast cancer cells. Melittin on its own reduced cancer cell growth & can be produced synthetically. One venom concentration killed cancer cells within 1 hour with minimal harm to other cells pic.twitter.com/UZOweUwtg5
— Massimo (@Rainmaker1973) July 9, 2026
While the findings remain preclinical and no human trials have begun, the work offers potential avenues for synthetic compounds that could one day complement existing therapies.
Breast cancer remains the most common cancer among U.S. women, with an estimated 321,910 new invasive cases projected in 2026 and about 42,140 deaths.
Triple-negative breast cancer, which lacks estrogen receptor, progesterone receptor, and HER2 targets, accounts for roughly 10-15% of cases overall and carries higher mortality due to limited targeted options and more aggressive behavior. HER2-enriched (hormone receptor-negative, HER2-positive) tumors represent about 4-5% of cases.
Lab Findings on Venom and Melittin
The study published September 1, 2020, in the peer-reviewed journal npj Precision Oncology, tested venom from 312 honeybees and bumblebees. Honeybee venom and its main component, melittin (about 50% of the venom), rapidly destroyed triple-negative and HER2-enriched breast cancer cells.
A specific concentration induced 100% cancer cell death within 60 minutes with minimal effects on normal cells. Melittin could be produced synthetically and mirrored most of the venom’s anticancer effects.
“We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells,” said lead researcher Dr. Ciara Duffy. “The venom was extremely potent.”
Melittin disrupted cancer cell membranes and suppressed EGFR and HER2 receptor activation by interfering with phosphorylation and downstream signaling pathways. Engineered versions showed improved targeting. In mouse models, melittin plus docetaxel reduced tumor growth more effectively than either alone.
History and Broader Medicinal Use
Bee venom has been used in traditional medicine for thousands of years. Ancient Egyptians, Greeks, Chinese, and Indians applied it — known as apitherapy — for arthritis, rheumatism, inflammation, and pain. Hippocrates reportedly used it therapeutically. Modern studies have examined its anti-inflammatory, antimicrobial, and potential neuroprotective properties.
Early scientific interest in anticancer effects dates to a 1950 Nature report on reduced tumor growth in plants. The 2020 study provided detailed mechanisms for breast cancer subtypes.
Later research, including 2024 studies, has explored melittin’s anti-metastatic effects and synergies with other treatments in cell models.
Current Status and Future Outlook
The approach is still preclinical. No human clinical trials for melittin or honeybee venom in breast cancer treatment have been reported. Researchers have called for further studies on dosing, toxicity, delivery methods, and safety before any clinical use.
Interest persists because triple-negative and certain HER2-enriched cancers disproportionately affect younger women and Black women, who face higher mortality rates. Synthetic melittin could offer a targeted tool if safety and efficacy are established in future trials.
Provided by Dallas Express
